At a glance
- Originator Uriach
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 20 Jan 2004 Discontinued - Preclinical for Rheumatic disorders in Spain (unspecified route)
- 18 Sep 2002 Preclinical trials in Rheumatic disorders in Spain (unspecified route)